7TM Pharma completes positron emission tomography preclinical research program to successfully demonstrate peripheral restriction of its CB1 receptor antagonist TM38837

Press Release Monday, July 12, 2010

7TM Pharma receives milestone payment from asthma and allergy collaboration

Press Release Wednesday, May 26, 2010

A potential new treatment for cancer supportive care and gastrointestinal diseases

Press Release Thursday, April 22, 2010

7TM Pharma successfully conducts clinical phase I trial with its second generation CB1 receptor antagonist

Press Release Thursday, February 04, 2010

7TM Pharma closes a financing round and sells certain early stage discovery assets and technology to OSI Pharmaceuticals

Press Release Thursday, January 15, 2009